A Bitter Reality: Older Americans Ditch Weight Loss Drugs in Droves
At 75, Mary Bucklew thought she had tried everything to lose weight – exercise, diet after diet. But the scale seemed unforgiving, constantly hovering just above her ideal target. That was until a new medication came into the picture. Ozempic, a GLP-1 drug approved for diabetes treatment, became her unlikely savior. In six short months, she lost 25 pounds and felt like a new person – walking and biking with renewed vigor.
Bucklew's story is not unique. A growing number of older Americans are quitting weight loss medications in droves, only to regrow the weight they lost. This trend has sparked concern among healthcare professionals, who are struggling to understand why patients are discontinuing these life-changing medications so frequently.
The culprit? Side effects like nausea, vomiting, and diarrhea – symptoms that often drive people away from treatment altogether. For Linda Burghardt, 79, the experience was too much to bear. She started taking Wegovy for arthritis pain but soon found herself writhing in agony on the bathroom floor due to stomach upset. The medication was discontinued.
Muscle loss is another significant issue. As patients shed pounds, they also lose muscle mass – a process that accelerates with these medications. This can lead to frailty, falls, and fractures, all of which are devastating consequences for older adults.
The high rate of GLP-1 discontinuation may be linked to shortages, as well as the misconception that weight loss is temporary. Patients often don't grasp that these medications will need to be taken indefinitely to maintain weight loss benefits.
And then there's cost – a major barrier to accessing these life-saving treatments. Medicare coverage has been spotty at best, leaving many patients with bills that soar into the thousands each month. The Biden administration has taken steps to address this, capping out-of-pocket payments and negotiating prices with manufacturers. But will it be enough?
As the landscape of weight loss medications continues to evolve, one thing is clear: older Americans need access to affordable treatments that can transform their lives. It's time for Medicare to rethink its policy on Part D coverage for weight loss drugs – a move that could expand eligibility and make these life-saving medications more accessible to those who need them most.
For Bucklew, the journey continues – albeit with a new medication. Though her initial dose was increased due to a recent sleep apnea diagnosis, she remains optimistic about Zepbound's ability to stabilize her weight. As she embarks on this next chapter, one thing is certain: she'll be watching her waistline closely.
At 75, Mary Bucklew thought she had tried everything to lose weight – exercise, diet after diet. But the scale seemed unforgiving, constantly hovering just above her ideal target. That was until a new medication came into the picture. Ozempic, a GLP-1 drug approved for diabetes treatment, became her unlikely savior. In six short months, she lost 25 pounds and felt like a new person – walking and biking with renewed vigor.
Bucklew's story is not unique. A growing number of older Americans are quitting weight loss medications in droves, only to regrow the weight they lost. This trend has sparked concern among healthcare professionals, who are struggling to understand why patients are discontinuing these life-changing medications so frequently.
The culprit? Side effects like nausea, vomiting, and diarrhea – symptoms that often drive people away from treatment altogether. For Linda Burghardt, 79, the experience was too much to bear. She started taking Wegovy for arthritis pain but soon found herself writhing in agony on the bathroom floor due to stomach upset. The medication was discontinued.
Muscle loss is another significant issue. As patients shed pounds, they also lose muscle mass – a process that accelerates with these medications. This can lead to frailty, falls, and fractures, all of which are devastating consequences for older adults.
The high rate of GLP-1 discontinuation may be linked to shortages, as well as the misconception that weight loss is temporary. Patients often don't grasp that these medications will need to be taken indefinitely to maintain weight loss benefits.
And then there's cost – a major barrier to accessing these life-saving treatments. Medicare coverage has been spotty at best, leaving many patients with bills that soar into the thousands each month. The Biden administration has taken steps to address this, capping out-of-pocket payments and negotiating prices with manufacturers. But will it be enough?
As the landscape of weight loss medications continues to evolve, one thing is clear: older Americans need access to affordable treatments that can transform their lives. It's time for Medicare to rethink its policy on Part D coverage for weight loss drugs – a move that could expand eligibility and make these life-saving medications more accessible to those who need them most.
For Bucklew, the journey continues – albeit with a new medication. Though her initial dose was increased due to a recent sleep apnea diagnosis, she remains optimistic about Zepbound's ability to stabilize her weight. As she embarks on this next chapter, one thing is certain: she'll be watching her waistline closely.